For early-stage disease, it is indicated in combination with endocrine therapy (tamoxifen or aromatase inhibitors) for adults with lymph node-positive, high-risk recurrence HR+/HER2- breast cancer; and as monotherapy or combined with fulvestrant for HR+/HER2- locally advanced or metastatic disease, including first-line endocrine therapy in postmenopausal women or post-endocrine progression settings (Yang et al., 2022). Here, ERBB2 is linked to metastatic neoplasm.